Molecular Drivers of Lung Cancer in Hispanics
Molecular Drivers of Lung Cancer in Hispanics
批准号:
10543164
负责人:
William Douglas Cress
金额:
$19.3万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-01-01 至 2024-12-31
关键词:
AddressAffinityAfrican American populationAgeAmerican Cancer SocietyAmerican Medical AssociationAutomobile DrivingBiologicalBiologyCancer CenterCancer EtiologyCancer PatientCancer cell lineCaucasiansCell Culture TechniquesCell LineCellular biologyCessation of lifeChimeric ProteinsChromosome 19DNA sequencingDataDiseaseDisparityEpidemicEpidermal Growth Factor ReceptorEventExonsFloridaFrequenciesFusion Protein ExpressionGene FusionGenesGenomicsGoalsHeadHigh PrevalenceHispanicHispanic PopulationsIndigenous AmericanJournalsKRAS2 geneLatinoLatino PopulationLiteratureLow PrevalenceLungLung AdenocarcinomaLung NeoplasmsMalignant NeoplasmsMalignant neoplasm of lungMass Spectrum AnalysisMethodologyMinorityModelingMolecularMutationMutation AnalysisNot Hispanic or LatinoOncogenicOncologyOncoproteinsPaperPatientsPatternPopulationPropertyProtein IsoformsProteinsPublishingRNARNA SplicingReagentRegistriesReportingResourcesRoleSTK11 geneSamplingSeminalSeriesSpecimenTailTestingThe Cancer Genome AtlasTherapeuticTranscriptWomanWorkclinically relevantcohortdriver mutationexome sequencinginsightlung cancer cellmenmortalitynever smokernew therapeutic targetnoveloverexpressionpatient registryrepositorytargeted treatmenttranscriptome sequencingtumortumorigenesis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
Lung malignancies are the leading cause of cancer death among Hispanic/Latino (H/L) men and second
among H/L women1. While H/L have surpassed African Americans as a minority nationally, they account for
only 3% (149 total) of patients characterized in the Cancer Genome Atlas (TCGA)2 and only 0.4% of patient-
derived oncological models in existence3. Among lung cancer patients, compared to Caucasians, H/Ls (1)
have double the mortality among never-smokers4-8; (2) present more frequently with late-stage disease7, 9; (3)
and are often not identified as being candidates for targeted therapy due to the lack of proper genomic
characterization of their lung cancers10-12. To address these disparities with respect to lung cancer, we
collected 163 lung tumor samples from H/L patients and subjected them to exome sequencing13. Notably, we
observed H/L lung adenocarcinoma patients have a very low prevalence of KRAS and STK11 mutations and a
high prevalence of EGFR mutations - a pattern that we13 and others14 find associated with Indigenous
American ancestry. We subjected 48 patients of those patients from the registry that lacked KRAS or EGFR
driver mutations to RNA sequencing to assess if known or unknown fusion-events might account for lung
cancer in this understudied population. Out of the 48 patient specimens, ten (21%) harbored potential
oncogenic transcript fusions. Half (5) of these patients had known MET fusions or expressed known
oncogenic isoforms of MET. Notably, the other five patient specimens expressed ADCK4-NUMBL fusion
transcript (three copies of Exon 15: Exon 2 fusions and two copies of Exon 15: Exon 3 fusions). DNA
sequencing does not reveal gene fusion; however, the ADCK4 and NUMBL genes are aligned head-to-tail in
chromosome 19 supporting the hypothesis that intergenic cis-splicing of ADCK4 (Exon 15) with NUMBL (Exon
2) drives expression of ADCK4-NUMBL chimeric transcripts. Similar transcripts have been detected in a few
cell lines but are not observed in the vast RNA sequencing data available via the TCGA, suggesting that these
transcripts are expressed commonly only in H/L patient samples. Based on the limited literature15-18, we
hypothesize that intergenic splicing of ADCK4 with NUMBL drives expression of ADCK4-NUMBL chimeric
transcripts and that these transcripts express oncoproteins with unique biological properties. To test these
hypotheses, we will 1) determine how expression of ADCK4-NUMBL chimeric proteins influence cell
biology, 2) establish novel patient-derived cell lines from H/L never smokers and 3) explore the
mechanisms leading to the expression of cis-spliced ADCK2-NUMBL transcripts. We anticipate that the
results of these studies will provide insight into the mechanisms driving the elevated lung cancer mortality
among H/Ls who do not smoke and identify novel therapeutic targets.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Molecular Drivers of Lung Cancer in Hispanics
-
批准号:10355864
-
项目类别:
-
资助金额:$23.63万
-
财政年份:2022
-
负责人:William Douglas Cress
-
依托单位:
Targeting centrosome‐mitotic kinases as a novel therapeutic approach against breast cancers in Hispanic/Latinas.
-
批准号:10705160
-
项目类别:
-
资助金额:$48.74万
-
财政年份:2022
-
负责人:William Douglas Cress
-
依托单位:
Targeting centrosome‐mitotic kinases as a novel therapeutic approach against breast cancers in Hispanic/Latinas.
-
批准号:10539820
-
项目类别:
-
资助金额:$48.32万
-
财政年份:2022
-
负责人:William Douglas Cress
-
依托单位:
Pre-Clinical Core
-
批准号:10438718
-
项目类别:
-
资助金额:$34.22万
-
财政年份:2021
-
负责人:William Douglas Cress
-
依托单位:
Pre-Clinical Core
-
批准号:10171104
-
项目类别:
-
资助金额:$33.23万
-
财政年份:2021
-
负责人:William Douglas Cress
-
依托单位:
Pre-Clinical Core
-
批准号:10676748
-
项目类别:
-
资助金额:$33.62万
-
财政年份:2021
-
负责人:William Douglas Cress
-
依托单位:
Integrated Program in Cancer and Data Science
-
批准号:10238072
-
项目类别:
-
资助金额:$42.79万
-
财政年份:2019
-
负责人:William Douglas Cress
-
依托单位:
Integrated Program in Cancer and Data Science
-
批准号:10018819
-
项目类别:
-
资助金额:$29.48万
-
财政年份:2019
-
负责人:William Douglas Cress
-
依托单位:
Cancer Research Workforce Development in FAIR Artificial Intelligence and Machine Learning
-
批准号:10405929
-
项目类别:
-
资助金额:$8.63万
-
财政年份:2019
-
负责人:William Douglas Cress
-
依托单位:
Integrated Program in Cancer and Data Science
-
批准号:10460990
-
项目类别:
-
资助金额:$44.11万
-
财政年份:2019
-
负责人:William Douglas Cress
-
依托单位:
Research Pilot Project
-
批准号:10005162
-
项目类别:
-
资助金额:$9.7万
-
财政年份:2017
-
负责人:William Douglas Cress
-
依托单位:
1/2 Southeast Partnership for Improving Research & Training in Cancer Health Disparities
-
批准号:10005129
-
项目类别:
-
资助金额:$30.15万
-
财政年份:2017
-
负责人:William Douglas Cress
-
依托单位:
Shared Resources Core: Puerto Rico Biobank
-
批准号:10249099
-
项目类别:
-
资助金额:$15.01万
-
财政年份:2012
-
负责人:William Douglas Cress
-
依托单位:
Shared Resource Core: Puerto Rico BioBank
-
批准号:10762079
-
项目类别:
-
资助金额:$22.8万
-
财政年份:2012
-
负责人:William Douglas Cress
-
依托单位:
Transcriptional Control of Mcl-1 and Bok/Mtd by E2F1
-
批准号:7342177
-
项目类别:
-
资助金额:$4.97万
-
财政年份:2003
-
负责人:William Douglas Cress
-
依托单位:
Transcriptional Control of Mcl-1 and Bok/Mtd by E2F1
-
批准号:7175321
-
项目类别:
-
资助金额:$27.03万
-
财政年份:2003
-
负责人:William Douglas Cress
-
依托单位:
Transcriptional Control of Mcl-1 and Bok/Mtd by E2F1
-
批准号:7010749
-
项目类别:
-
资助金额:$27.84万
-
财政年份:2003
-
负责人:William Douglas Cress
-
依托单位:
Transcriptional Control of Mcl-1 and Bok/Mtd by E2F1
-
批准号:7013409
-
项目类别:
-
资助金额:$4.72万
-
财政年份:2003
-
负责人:William Douglas Cress
-
依托单位:
Transcriptional Control of Mcl-1 and Bok/Mtd by E2F1
-
批准号:6800650
-
项目类别:
-
资助金额:$4.33万
-
财政年份:2003
-
负责人:William Douglas Cress
-
依托单位:
Transcriptional Control of Mcl-1 and Bok/Mtd by E2F1
-
批准号:7177377
-
项目类别:
-
资助金额:$4.85万
-
财政年份:2003
-
负责人:William Douglas Cress
-
依托单位:
海外基金